Investors focused on the Medical space have likely heard of Aeglea BioTherapeutics , but is the stock performing well in comparison to the rest of its sector peers? Let's take a closer look at the stock's year-to-date performance to find out.

Aeglea BioTherapeutics is a member of our Medical group, which includes 888 different companies and currently sits at #1 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.

The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. AGLE is currently sporting a Zacks Rank of #2 (Buy).

Over the past three months, the Zacks Consensus Estimate for AGLE's full-year earnings has moved 37.48% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.

Based on the most recent data, AGLE has returned 14.40% so far this year. In comparison, Medical companies have returned an average of 0.21%. This means that Aeglea BioTherapeutics is performing better than its sector in terms of year-to-date returns.

Looking more specifically, AGLE belongs to the Medical - Biomedical and Genetics industry, which includes 382 individual stocks and currently sits at #34 in the Zacks Industry Rank. Stocks in this group have gained about 8.10% so far this year, so AGLE is performing better this group in terms of year-to-date returns.

Investors with an interest in Medical stocks should continue to track AGLE. The stock will be looking to continue its solid performance.